COVID-19 Update: We are currently shipping orders daily. However, due to transit disruptions in some geographies, deliveries may be delayed. To provide all customers with timely access to content, we are offering 50% off Science and Technology Print & eBook bundle options. Terms & conditions.
Isocitrate Dehydrogenase Inhibitors in Cancer Chemotherapy - 1st Edition - ISBN: 9780323901970

Isocitrate Dehydrogenase Inhibitors in Cancer Chemotherapy, Volume 20

1st Edition

Editor: Robert Musiol
Hardcover ISBN: 9780323901970
Imprint: Academic Press
Published Date: 1st May 2022
Page Count: 200
Sales tax will be calculated at check-out Price includes VAT/GST

Institutional Subscription

Secure Checkout

Personal information is secured with SSL technology.

Free Shipping

Free global shipping
No minimum order.

Table of Contents

  1. Isocitrate dehydrogenase and its place in cellular metabolism
    2. Wild type and mutant IDH as drug target
    3. Holy grail of combination therapy? Possibilities and limitations of mono- and poli-therapies based on IDH1/2 inhibitors
    4. Two faced IDH. The good and bad in prognosis
    5. Inhibitors of IDH1/2 in leukemias
    6. Inhibitors of IDH1/2 in gliomas and other brain tumors
    7. Potential importance of IDH in gastrointestinal cancers
    8. Isocitrate dehydrogenases as target for theranostics
    9. Resistance emerging and therapeutic strategies
    10. Challenges and future perspectives


Isocitrate Dehydrogenase Inhibitors in Cancer Chemotherapy presents an in-depth and up-to-date compilation of research on isocitrate dehydrogenase as drug target to be used as a sensitizing agent in chemotherapy. The book brings a combination of medicinal, biological and chemical points-of-view to fully cover the subject. It discusses topics such as IDH place in cellular metabolism, mutant IDH as drug target, mono- and poli-therapies based on IDH1/2 inhibitors, and IDH1/2 inhibitors in leukemia, gliomas and other brain tumors, and potential importance in gastrointestinal cancers. Additionally, it discusses isocitrate dehydrogenases as target for theranostics, therapeutic strategies and future perspectives.

This is a valuable resource for cancer researchers, oncologists and members of the biomedical field who are interested to learn more about IDH inhibitors and their potential as sensitizing agents for chemotherapy.

Key Features

  • Presents comprehensive and up-to-date review of current trends in design IDH inhibitors and their use as adjuvant therapy
  • Contains summarized tables and schematic diagrams in each chapter to give a clear overview of the recent findings in a didactic manner
  • Brings not only relevant information of current research but also new ideas and suggestions for further investigations to help advance the field


Cancer researchers, medical scientists, clinicians, graduate students, pharmacologists


No. of pages:
© Academic Press 2022
1st May 2022
Academic Press
Hardcover ISBN:

Ratings and Reviews

About the Editor

Robert Musiol

Prof. Dr Robert Musiol received a PhD in organic chemistry in 2005 and habilitation in pharmacy in 2013. For roughly twenty years he is connected with University of Silesia in Katowice, Poland, where he teaches medicinal chemistry, pharmacology and toxicology. His scientific interest is focused on drug design and particularly polypharmacological design of potential anticancer drugs. Recently he is involved in redesign of IDH1 inhibitors towards multi-kinase activity. He is a co-author of more than one hundred scientific papers and thirty patents. Being involved in teaching and popularizing science, he was supervisor of four doctorates and more than forty master’s degree students.

Affiliations and Expertise

Professor, University of Silesia in Katowice, Poland